Loading company
Equillium, Inc.
EQ · Nasdaq · ·
$1.62-4.4%Sep 29 close
- 1M
- -32.4%
- 6M
- -7.7%
- 1Y
- +12.9%
- 5Y
- -76.1%
EQ · Nasdaq · ·
$1.62-4.4%Sep 29 close
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $4.4M | $9.2M | -52.32% |
| Profit | -$4.7M | -$5.7M | +18.23% |
| Profit per share | -$0.04 | -$0.16 | +75.00% |
| Free Cash Flow | -$4.2M | -$3M | -38.67% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Equillium, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Equillium, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.